22 studies found for:    "Shigellosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Withdrawn Shigella Sonnei OSPC-rDT Conjugate Vaccine
Condition: Shigellosis
Intervention: Drug: CP
2 Completed Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
Conditions: Immunogenicity;   Shigellosis
Intervention: Biological: Shigella Sonnei O-SPC/rBRU
3 Completed Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
Condition: Shigellosis
Intervention: Biological: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
4 Active, not recruiting Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
Condition: Shigellosis
Interventions: Biological: 1790GAHB vaccine;   Biological: GAHB-Placebo
5 Active, not recruiting A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Condition: Shigellosis
Interventions: Biological: 1790GAHB vaccine;   Biological: GAHB-Placebo
6 Completed
Has Results
Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
Condition: Shigellosis
Intervention: Biological: Shigella conjugate vaccines
7 Completed Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
Condition: Shigella
Interventions: Biological: CVD 1208S, a Shigella flexneri 2a live, oral vaccine;   Other: Placebo
8 Terminated Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb
Condition: Shigella
Intervention: Biological: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
9 Terminated Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa
Condition: Shigella
Interventions: Biological: CVD 1208S, a Shigella flexneri 2a live, oral vaccine;   Other: Placebo
10 Recruiting Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3
Condition: Shigella Infection
Interventions: Other: Placebo;   Biological: WRSs2;   Biological: WRSs3
11 Completed Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine
Condition: Shigella Infection
Intervention: Biological: SC599
12 Completed Therapeutic Induction of Endogenous Antibiotics
Condition: Shigellosis
Interventions: Biological: Sodium Butyrate;   Biological: Saline
13 Completed Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
Conditions: Dysentery;   Shigella;   Diarrhea
Interventions: Biological: WRSS1 vaccine;   Biological: Placebo vaccine
14 Completed Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
Condition: Shigellosis
Intervention: Biological: Invaplex 50 Vaccine
15 Completed Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
Condition: Shigellosis
Intervention: Biological: Shigella vaccine
16 Recruiting Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
Conditions: Soil-transmitted Helminthiasis;   Schistosomiasis;   Strongyloidiasis;   Shigellosis;   Intestinal Salmonellosis;   Campylobacteriosis;   Aeromonas Spp. Infections;   Giardiasis;   Amoebiasis;   Dientamoebiasis;   Cryptosporidium Spp. Infections
Interventions: Procedure: Stool culturing for pathogenic bacteria;   Procedure: Kato-Katz technique;   Procedure: Baermann technique;   Device: Mini-FLOTAC;   Device: Crypto/Giardia Duo Strip;   Procedure: Formalin-ether concentration technique;   Device: CCA RDT;   Procedure: Koga agar plate culture;   Procedure: Kinyoun staining;   Device: Multiplex PCR;   Procedure: Metagenomics analysis
17 Active, not recruiting Safety Study of Live Shigella Vaccine in Bangladeshi Adults and Children
Condition: Diarrhea
Intervention: Biological: WRSS1
18 Completed Zinc Supplementation in Shigella Patients
Condition: Testing Effect of Intervention
Intervention: Drug: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
19 Active, not recruiting A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals
Conditions: Viral Pneumonia;   Bronchitis;   Infantile Diarrhea;   Bacillary Dysentery;   Virus Hepatitis
Intervention:
20 Completed Invaplex 50 Vaccine Dose-Ranging
Condition: Diarrhea
Intervention: Biological: Shigella flexneri 2a Invaplex 50

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years